<?xml version="1.0" encoding="UTF-8"?>
<p>Entecavir is a carbocyclic analogue of 20-deoxyguanosine that has proved to be effective in adult patients [
 <xref ref-type="bibr" rid="CR113">113</xref>]. Resistance is rare, even after 5 years of treatment [
 <xref ref-type="bibr" rid="CR114">114</xref>]. It has been approved by the FDA for treatment of adolescents aged 16 years or older. The recommended dose is 0.5 mg once daily for nucleoside-na√Øve patients and 1 mg/day for lamivudine-resistant patients. A phase III clinical trial in children as young as 2 years old is underway.
</p>
